Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 22:16:4321-4328.
doi: 10.2147/IJGM.S422523. eCollection 2023.

The Emerging Roles and Mechanisms of PAQR3 in Human Cancer: Pathophysiology and Therapeutic Implications

Qiang Guo #  1   2 , Xiao-Li Liu #  3 , Kui Zhai #  4 , Cheng Chen  1 , Xi-Xian Ke  1 , Jun Zhang  2 , Gang Xu  1
Affiliations
Review

The Emerging Roles and Mechanisms of PAQR3 in Human Cancer: Pathophysiology and Therapeutic Implications

Qiang Guo et al. Int J Gen Med. .

Abstract

Cancer was one of the common causes of death in the world, and it was increasing year by year. At present, Progestin and AdipoQ receptor family member 3 (PAQR3) was widely studied in cancer. It has been found that PAQR3 was down regulated in various cancers, such as the gastric cancer, osteosarcoma, glioma, hepatocellular carcinoma, acute lymphoblastic leukemia, laryngeal squamous cell carcinoma, esophageal cancer, breast cancer, non-small cell lung cancer, and colorectal cancer. The decreased expression of PAQR3 was associated with short overall survival and disease-free survival in patients with gastric cancer, hepatocellular carcinoma, laryngeal squamous cell carcinoma, esophageal cancer, breast cancer, and non-small cell lung cancer. PAQR3 could inhibit cancer progression by using the Ras/Raf/MEK/ERK, PI3/AKT, EMT and other mechanisms, and was negatively regulated by the miR-543, miR-15b-5p and miR-15b. The roles and signaling mechanisms of PAQR3, and the relationship between the expression of PAQR3 and prognosis in cancer progression are reviewed in this article, and provides new tumor marker and idea to guide cancer treatment.

Keywords: PAQR3; disease-free survival; overall survival; tumor suppressor.

PubMed Disclaimer

Conflict of interest statement

Qiang Guo, Xiao-Li Liu and Kui Zhai are co-first authors for this study. The authors declare that they have no competing interests in this work.

Figures

Figure 1
Figure 1
The miRNAs-PAQR3 signaling pathway in cancer progression.
Figure 2
Figure 2
Downstream signaling of PAQR3 in cancer progression.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi:10.3322/caac.21590 - DOI - PubMed
    1. Ghafoor Q, Baijal S, Taniere P, O’Sullivan B, Evans M, Middleton G. Epidermal Growth Factor Receptor (EGFR) kinase inhibitors and non-small cell lung cancer (NSCLC) - advances in molecular diagnostic techniques to facilitate targeted therapy. Pathol Oncol Res. 2018;24(4):723–731. doi:10.1007/s12253-017-0377-1 - DOI - PubMed
    1. Hsu PC, Jablons DM, Yang CT, You L. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci. 2019;20(15):3821. doi:10.3390/ijms20153821 - DOI - PMC - PubMed
    1. Zhang Y, Tang M, Guo Q, Xu H, Yang Z, Li D. The value of erlotinib related target molecules in kidney renal cell carcinoma via bioinformatics analysis. Gene. 2022;816:146173. doi:10.1016/j.gene.2021.146173 - DOI - PubMed
    1. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–196. doi:10.1016/j.ejphar.2018.07.034 - DOI - PubMed